Opioid Treatment Program (OTP)-Pharmacy Collaboration for Methadone Maintenance Treatment

Early Phase 1

Completed

Brief Summary: The overarching goal of this pilot study is to explore the feasibility, acceptability, and patient/provider satisfaction of pharmacy-based administration and dispensing of methadone for opioid use disorder. The results gained will inform the development of a future multisite randomized clinical trial.

Detailed Description: The study will use a non-randomized, prospective, single group design. Twenty long-term, clinically-stable methadone maintenance treatment (MMT) patients who receive between 6- and 13-days methadone take-home doses will be enrolled in the study where their methadone take-home administration and dispensing will be transferred to a community pharmacy for 3 months. Participants will also complete three follow-up assessments at 1-month, 2-months, and 3-months after the baseline visit to collect clinical and safety information since the previous assessment. Primary outcomes will be focused on feasibility measures (recruitment, accessibility to methadone treatment, substance use, medication call back success, and retention in treatment). Secondary outcomes will be focused on self-reported satisfaction measures from MMT providers (e.g., physician, physician assistant, nurse, and counselor) pharmacists, and patient participants.

Recruitment & Eligibility

Inclusion Criteria

Patient aged 18 or older receiving methadone treatment at Morse Clinic in Raleigh or Zebulon, NC.
Able to provide informed written consent to participate in the pilot study.
Receiving a stable methadone dose between 5 mg and 160 mg.
Having all negative drug tests (except for prescribed methadone and ethanol) at the OTP for the past 12 months.
No missed call-backs in the past 12 months.
No signs/symptoms of a co-occurring major mental illness (i.e., thought disorder, thoughts of harm to self or others, delusions or hallucinations, cognitive impairment compromising informed consent to study procedures and requirements).
Meeting the federal and state regulations for eligibility to receive between 6- and 13-days of take-home methadone and receiving this level of take-home doses at the time of study enrollment.
If female, using adequate birth control methods.

Exclusion Criteria

Have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study.
Have chronic pain requiring ongoing pain management with opioid analgesics.
Prisoner status or pending legal action that could prevent participation in study activities
Legal order for treatment (e.g., parole, probation, or pre-trial)
Pregnant or breastfeeding at the time of screening.

Arm && Interventions

Group	Intervention	Description
Pharmacy-based methadone treatment	Pharmacy-based methadone administration and dispensing	Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.

Primary Outcome Measures

Name	Time	Method
Recruitment Rate	3 months	The recruitment rate will be assessed on a monthly basis (e.g, Month 1, 2 and 3) until the enrollment target is reached. The recruitment rate is operationalized as the total number of participants consented in one month.
Treatment Adherence	Up to 3 months per participant	Adherence to pharmacy-based methadone treatment will be defined as the percentage of methadone take-home doses dispensed at the pharmacy out of the total number of take home doses prescribed.
Treatment Retention	Up to 3 months per participant	Treatment retention will be determined by the percentage of participants who remain in treatment at the pharmacy during the 3-month follow-up phase.
Opioid and Other Substance Use	Up to 3 months per participant	The percentage of positive urine drug screens over the study duration will be examined.

Secondary Outcome Measures

Name	Time	Method
Treatment Satisfaction	Over 3 months of treatment	Participant satisfaction with treatment delivery will be measured on a monthly basis and a percentage of overall monthly ratings (combined) of satisfied or very satisfied will be calculated.
Adverse Events	Up to 3 months per participant	We will measure the prevalence of any fatal or non-fatal substance-related overdose and any substance-related emergency department visit or hospitalization.
Percentage of Participants With Methadone Call Backs With Evidence of Tampering.	3 months	Percentage of participants with call backs with evidence of methadone tampering.

Locations (3): Health Park Pharmacy
🇺🇸
Raleigh, North Carolina, United States
Morse Clinic of Zebulon
🇺🇸
Zebulon, North Carolina, United States
Morse Clinic of North Raleigh
🇺🇸
Raleigh, North Carolina, United States